Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors Metastatic to the Liver 1Melanoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Rose Bengal B × Clear all
NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1/2 Unknown
50 enrolled
Dermatologic

Melanoma

NCT02693067 2023-02-08

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
12 enrolled
EndocrineNET

Neuroendocrine Tumors Metastatic to the Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡